Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 275

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 332
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Small intestine adenocarcinoma

Not recruiting

Study on the Effectiveness of Chemotherapy with Fluorouracil, Capecitabine, and Oxaliplatin for Patients with Small Bowel Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Hepatocellular carcinoma

Not recruiting

Study on Durvalumab and Tremelimumab for Liver Cancer Patients Undergoing Electroporation Ablation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Renal failure

Not recruiting

Study Comparing Anakinra and Prednisone for Treating Gout Flare in Patients with Advanced Kidney Disease or Kidney Transplant

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Luveltamab Tazevibulin (STRO-002) for Infants and Children Under 12 with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:STRO-002
  • Sponsor:Sutro Biopharma Inc.

Hodgkin's disease+6

Not recruiting

Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic lupus erythematosus

Not recruiting

Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Metastatic malignant melanoma

Not recruiting

Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Huyabio International LLC

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.